Overview
WALD market data
Price History
WALD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.01 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.14 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.72 – $3.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $216.5 · P/B 0.52 · P/S 0.54.
Company News
Waldencast Receives FDA Approval For Obagi Saypha ChIQ Injectable Hyaluronic ACID GelBenzinga · Jun 15, 2026, 1:10 PM
Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $3Benzinga · Jun 2, 2026, 3:10 PM
Waldencast shares are trading higher after the company announced that it will sell its Obagi Medical unit to Bridgepoint for as much as $460MBenzinga · Jun 1, 2026, 5:23 PM
Waldencast Sells Obagi Medical To Bridgepoint For Up To $460MBenzinga · Jun 1, 2026, 11:02 AM
Obagi Medical Announces New Skincare And Filler Data At Nashville SCALE MeetingBenzinga · May 15, 2026, 12:20 PM